Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$89.18
+1.8%
$91.92
$81.04
$134.63
$221.28B0.3511.05 million shs12.39 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$31.12
-3.1%
$34.72
$29.25
$170.47
$12.03B1.866.82 million shs5.68 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+1.81%-4.56%-0.23%-10.55%-32.31%
Moderna, Inc. stock logo
MRNA
Moderna
-3.11%-4.72%-7.33%-22.45%-71.86%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
5 of 5 stars
4.35.05.03.92.73.33.8
Moderna, Inc. stock logo
MRNA
Moderna
4.1085 of 5 stars
4.01.00.04.61.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.65
Moderate Buy$117.1231.33% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$59.0089.59% Upside

Current Analyst Ratings Breakdown

Latest MRNA and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$128.00 ➝ $105.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$111.00 ➝ $45.00
2/14/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$45.00
2/14/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
2/12/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $115.00
2/11/2025
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$41.00 ➝ $34.00
2/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$121.00 ➝ $100.00
(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.51$3.09 per share28.82$14.85 per share6.01
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.76N/AN/A$28.33 per share1.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.7313.259.010.7726.67%45.35%17.36%4/24/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)

Latest MRNA and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16N/AN/AN/A$15.59 billionN/A
2/4/2025Q4 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.85$1.72-$0.13$1.48$15.51 billion$15.62 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.63%+5.73%48.14%14 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest MRNA and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/28/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.813.32%3/17/20253/17/20254/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.79
1.36
1.15
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
69,0002.53 billion2.53 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable

Recent News About These Companies

Moderna brand chief Kate Cronin leaves for 'next chapter'
Citi Keeps Their Hold Rating on Moderna (MRNA)
The Trump Administration Threatens mRNA Research
The anti-vax culture war on mRNA just got worse
Brokerages Set Moderna, Inc. (NASDAQ:MRNA) Target Price at $59.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$89.18 +1.58 (+1.80%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$89.15 -0.03 (-0.03%)
As of 03/28/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna stock logo

Moderna NASDAQ:MRNA

$31.12 -1.00 (-3.11%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$31.22 +0.11 (+0.34%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.